LENZ · LENZ Therapeutics, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $21.48M | $19.09M | $0 | — | — | — | — | |
| — | $418K | $0 | — | — | — | — | |
| — | $18.67M | $0 | — | — | — | — | |
| — | 97.81% | — | — | — | — | — | |
| $3.79M | $18.67M | $29.8M | $59.5M | $72.79M | $37.93M | $9.12M | |
| — | — | — | $40.97M | $32.85M | $22.51M | $4.38M | |
| $151.57M | $91.14M | $28.81M | $12.93M | — | — | — | |
| — | $287K | $58K | $15K | $2.35M | $734K | $121K | |
| $85.4M | — | $58.61M | $72.43M | $105.64M | $60.44M | $13.5M | |
| — | $110.23M | $58.61M | — | — | — | — | |
| -$135.66M | -$91.14M | -$58.61M | -$72.43M | -$105.64M | -$60.44M | -$13.5M | |
| — | -477.46% | — | — | — | — | — | |
| — | -$90.85M | -$58.55M | -$72.41M | -$103.29M | -$59.71M | -$13.38M | |
| $10.1M | $9.76M | $8.55M | $2.19M | — | — | — | |
| $9.66M | $9.51M | $8.84M | $2.28M | $4.59M | -$10.32M | -$54.87M | |
| — | -$197K | $1.34M | — | — | — | — | |
| — | -$81.63M | -$49.77M | -$70.15M | — | — | — | |
| — | $502K | $1000 | -$179K | $0 | $0 | $0 | |
| -$126M | -$82.13M | -$49.77M | -$69.97M | -$101.05M | -$70.76M | -$68.37M | |
| — | -430.25% | — | — | — | — | — | |
| -$126.67M | -$82.08M | -$49.58M | -$69.96M | — | — | — | |
| USD/shares | — | -$2.85 | -$2.34 | -$35.71 | -$12.88 | -$17.15 | — |
| USD/shares | — | -$2.85 | -$2.34 | -$35.71 | -$12.88 | -$17.15 | — |
| shares | — | 28.81M | 21.28M | 1.96M | 7.84M | 4.13M | 326.3K |
| shares | — | 28.81M | 21.28M | 1.96M | 7.84M | 4.13M | 326.3K |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 301 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment | $19,088,000 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| License | $17,500,000 | $0 |
| Product | $1,588,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$91,138,000 | -$58,610,000 | -$72,429,000 |
Operating Margin by Segment (%)
| Component | FY2025 |
|---|---|
| Reportable Segment | -477.5% |